Joint health study for severe hemophilia A patients on new therapies
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate or severe hemophilia A.
- You are currently on a regular treatment (prophylaxis) with either emicizumab or efanesoctocog alfa for at least 2 months.
- You are older than 6 months.
- You do not have an active factor VIII inhibitor (more than 0.5 Bethesda units).
- You do not have any other bleeding disorder besides hemophilia A.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
This study compares two preventive treatments for severe hemophilia A—emicizumab versus factor VIII—to see how they affect joint and bone health. It may help you and others understand which option better protects joints and bones over the next several years.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
This study tests how well a new factor VIII medicine, efanesoctocog alfa, protects your joints over time. It's for people with moderate or severe hemophilia A who are just starting this treatment.
This study compares how two different hemophilia A treatments affect bone strength and health in men over time. Researchers will track bone density and collect blood samples to understand whether one treatment protects bones better than the other.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.